Cancer Family
Digestive System Neoplasm
CI-CAN-00000012Explore in graph →
Non-malignant4,732 active trials43 approved drugs557 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000012Explore in graph →
Clinical trials
22,051 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06598033 | Vitamin C Plus Cordyceps to Quality of Life in Patients With Terminal Stage Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| NCT06601283 | Vitamin C Plus Cordyceps to Chemotherapy Related Anemia in Pancreatic Cancer | recruiting | Phase 2 / Phase 3 | 50 | Fudan UniversityOTHER | 1 | Nov 26, 2024 | clinicaltrials |
| recruiting |
| Phase 1 / Phase 2 |
| 358 |
| GI Innovation, Inc.INDUSTRY |
| 2 |
| Nov 25, 2024 |
| clinicaltrials |
| NCT03812874 | A Study of PTX-9908 Injection for Non-resectable HCC with TACE | recruiting | Phase 1 / Phase 2 | 50 | TCM Biotech International Corp.INDUSTRY | 1 | Nov 21, 2024 | clinicaltrials |
| NCT05738434 | Camrelizumab in Combination With Apatinib Mesylate Plus Short-course Chemotherapy for Advanced ESCC | recruiting | Phase 2 | 188 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Nov 21, 2024 | clinicaltrials |
| NCT06301399 | Rituximab Combined With Prior Therapy in Advanced Hepatocellular Carcinoma: Efficacy & Safety Study | recruiting | Phase 2 | 20 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Nov 20, 2024 | clinicaltrials |
| NCT06313190 | Combination of SBRT and Immunotherapy in Small Hepatocellular Carcinoma (HSBRT2402)(HSBRT2402) | recruiting | Phase 2 | 140 | Sun Yat-sen UniversityOTHER | 1 | Nov 18, 2024 | clinicaltrials |
| NCT06612281 | Evaluation of Gixam's Performance in a FIT Negative Population | recruiting | Phase 2 | 400 | Jubaan Ltd.INDUSTRY | 1 | Nov 14, 2024 | clinicaltrials |
| NCT06532799 | TIL Therapy Combined With Pembrolizumab for Advanced or Metastatic Refractory Stomach and Esophageal Cancer(BAH250) | recruiting | Phase 1 / Phase 2 | 75 | Essen BiotechOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06684600 | Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 35 | Peking UniversityOTHER | 1 | Nov 12, 2024 | clinicaltrials |
| NCT06411600 | Combination Therapy for BRAF-V600E Metastatic CRCm(BRAVE) | recruiting | Phase 2 | 94 | Vall d'Hebron Institute of OncologyOTHER | 1 | Nov 8, 2024 | clinicaltrials |
| NCT03874026 | Study of Folfiri/Cetuximab in FcGammaRIIIa V/V Stage IV Colorectal Cancer Patients(CIFRA) | recruiting | Phase 2 | 34 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT06341764 | Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma | recruiting | Phase 2 | 38 | National Cancer Institute, NaplesOTHER | 1 | Nov 7, 2024 | clinicaltrials |
| NCT05254171 | Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer(ASPIRE) | recruiting | Phase 2 / Phase 3 | 600 | Panbela Therapeutics, Inc.INDUSTRY | 10 | Nov 6, 2024 | clinicaltrials |
| NCT06530303 | Biological Tumor Infiltrating Lymphocytes Therapy With Immunotherapy for Colon and Rectum Cancer(BAH248) | recruiting | Phase 1 / Phase 2 | 85 | Essen BiotechOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06675201 | Neoantigen Vaccines in Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 165 | Sichuan UniversityOTHER | 1 | Nov 5, 2024 | clinicaltrials |
| NCT06389760 | Nimotuzumab Combined With mFOLFIRINOX/GX as Postoperative Adjuvant Therapy in Pancreatic Cancer | recruiting | Phase 2 | 57 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 1 | Oct 31, 2024 | clinicaltrials |
| NCT06664996 | Sintilimab Combined SBRT As Neoadjuvant Therapy for Resectable HCC with PVTT | recruiting | Phase 2 | 33 | West China HospitalOTHER | 1 | Oct 30, 2024 | clinicaltrials |
| NCT06663059 | Adebrelimab Neoadjuvant Treatment for Resectable ESCC: 2 vs 4 Cycles Study | recruiting | Phase 2 | 80 | Tang-Du HospitalOTHER | 1 | Oct 29, 2024 | clinicaltrials |
| NCT06207656 | Study to Evaluate the Efficacy and Safety of Cetuximab in Combination with Encorafenib Plus Binimetinib As Induction Treatment in BRAF V600E Mutated MSS Initially Resectable or Potentially Resectable Advanced Colorectal Cancer(CEBBRA) | recruiting | Phase 2 | 70 | Spanish Cooperative Group for the Treatment of Digestive Tumours (TTD)OTHER | 1 | Oct 21, 2024 | clinicaltrials |
| NCT04547166 | A Clinical Study to Evaluate Efficacy and Safety of Serplulimab（HLX10） Combined With Bevacizumab（HLX04) and Chemotherapy (XELOX) in Patients With Metastatic Colorectal Cancer (mCRC) | recruiting | Phase 2 / Phase 3 | 568 | Shanghai Henlius BiotechINDUSTRY | 2 | Oct 17, 2024 | clinicaltrials |
| NCT05260385 | To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors | recruiting | Phase 1 / Phase 2 | 133 | Beijing Konruns Pharmaceutical Co., Ltd.INDUSTRY | 1 | Oct 17, 2024 | clinicaltrials |
| NCT06646588 | Fruquintinib in Combination With Tislelizumab Followed by Radiotherapy in Esophageal Squamous Cell Carcinoma(SJZ-RMEEC01) | recruiting | Phase 2 | 67 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 17, 2024 | clinicaltrials |
| NCT04183712 | Target Therapy With GEMOX in Recectable Gallbladder Carcinoma Patients Monitored by ctDNA | recruiting | Phase 2 | 102 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05882370 | TIPS Plus Cadonilimab in Advanced HCC with Tumor Thrombosis-associated Portal Hypertension:a Prospective, Single-arm, Phase II Study | recruiting | Phase 2 | 30 | Fei GaoOTHER | 1 | Oct 16, 2024 | clinicaltrials |
| NCT05462496 | Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer | recruiting | Phase 2 | 25 | Icahn School of Medicine at Mount SinaiOTHER | 1 | Oct 15, 2024 | clinicaltrials |
| NCT05440864 | Durvalumab and Tremelimumab in Resectable HCC((NEOTOMA)) | recruiting | Phase 2 | 28 | University Health Network, TorontoOTHER | 3 | Oct 10, 2024 | clinicaltrials |
| NCT06184698 | Liposomal Irinotecan and Leucovorin/5-fluorouracil Plus Bevacizumab in Metastatic Colorectal Cancer | recruiting | Phase 2 | 173 | Hebei Medical University Fourth HospitalOTHER | 1 | Oct 9, 2024 | clinicaltrials |
| NCT05628038 | The Combination of Hypofractionated Radiotherapy and Immunotherapy in Locally Recurrent Rectal Cancer(TORCH-R) | recruiting | Phase 2 | 93 | Fudan UniversityOTHER | 1 | Oct 1, 2024 | clinicaltrials |
| NCT02919644 | Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.(COREVAX-1) | recruiting | Phase 2 | 19 | Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCSOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT03736863 | A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | recruiting | Phase 2 | 147 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06493760 | A Phase 2 Study of SSGJ-707 in Metastatic Colorectal Cancer Patients | recruiting | Phase 2 | 130 | Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.INDUSTRY | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06510660 | Adebrelimab ±Induction Chemotherapy Followed by Concurrent Chemoradiotherapy for Unresectable Locally Advanced ESCC(RICE) | recruiting | Phase 2 | 48 | Fujian Medical University Union HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06586242 | Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy(EASOPCWAAC) | recruiting | Phase 2 | 194 | Xijing HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06603376 | Irinotecan Hydrochloride Liposome Injection (Ⅱ) Combined with Fluorouracil, Folinic Acid, Vermofenib and Cetuximab in First-line Treatment of BRAFV600E Mutated Advanced Colorectal Cancer | recruiting | Phase 2 | 75 | Shanghai Changzheng HospitalOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT06572319 | Disitamab Vedotin Plus Trastuzumab in Patients With HER2 Positive GC/GEJ Patiens | recruiting | Phase 1 / Phase 2 | 35 | Zhejiang Cancer HospitalOTHER | 1 | Aug 27, 2024 | clinicaltrials |
| NCT06185556 | COLDFIRE-III Trial: Efficacy of Irreversible Electroporation and Stereotactic Body Radiotherapy for Perivascular and Peribiliary Colorectal Liver Metastases(COLDFIRE-III) | recruiting | Phase 2 / Phase 3 | 78 | Amsterdam UMC, location VUmcOTHER | 1 | Aug 23, 2024 | clinicaltrials |
| NCT04770207 | Intra-tumor Injection of Drug-eluting Microspheres With Multiple Drugs | recruiting | Phase 2 | 100 | Second Affiliated Hospital of Guangzhou Medical UniversityOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06563986 | FTD-TPI, Bevacizumab, and Radioembolization With 166Ho-microspheres in Refractory Metastatic Colorectal Cancer(STARLIGHT) | recruiting | Phase 2 | 40 | UMC UtrechtOTHER | 1 | Aug 21, 2024 | clinicaltrials |
| NCT06560528 | Disitamab Vedotin Combined With Tislelizumab and Capecitabine in the Perioperative Treatment of Locally Advanced Gastric Cancer With HER2 Overexpression | recruiting | Phase 2 | 40 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Aug 19, 2024 | clinicaltrials |
| NCT06555471 | A Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | recruiting | Phase 2 | 40 | The First Affiliated Hospital with Nanjing Medical UniversityOTHER | 1 | Aug 15, 2024 | clinicaltrials |
| NCT04680260 | OPTIMIzation of Treatment SElection and Follow up in Oligometastatic Colorectal Cancer(OPTIMISE) | recruiting | Phase 2 | 350 | Karen-Lise Garm SpindlerOTHER | 1 | Aug 14, 2024 | clinicaltrials |
| NCT06079346 | A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer(STOP-PC) | recruiting | Phase 2 / Phase 3 | 455 | Oncotelic Inc.INDUSTRY | 1 | Aug 13, 2024 | clinicaltrials |
| NCT06341296 | Phase II Study of Irinotecan Liposomes in First-line Treatment of Metastatic Colorectal Cancer | recruiting | Phase 2 | 86 | West China HospitalOTHER | 1 | Aug 12, 2024 | clinicaltrials |
| NCT06547203 | Cetuximab, Irinotecan, Toripalimab in RAS/BRAF Wild-type Ultraselected Right-sided Colorectal Cancer Study | recruiting | Phase 2 | 34 | Sun Yat-sen UniversityOTHER | 1 | Aug 9, 2024 | clinicaltrials |
| NCT05177133 | Anti-PD-1 and CapOx for the First-line Treatment of dMMR Esophagogastric Cancer (AuspiCiOus)(AuspiCiOus) | recruiting | Phase 2 | 25 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06534762 | Milaberon in Advanced Solid Tumors: an Open, Multicenter Clinical Study | recruiting | Phase 2 | 260 | Zhejiang Provincial People's HospitalOTHER | 1 | Aug 2, 2024 | clinicaltrials |
| NCT06454578 | Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative Resection | recruiting | Phase 2 | 30 | Qilu Hospital of Shandong UniversityOTHER | 1 | Aug 1, 2024 | clinicaltrials |
| NCT06138028 | Sintilimab and Chemotherapy Sequential Radiotherapy in Advanced Esophageal Cancer | recruiting | Phase 2 / Phase 3 | 90 | Qingdao Central HospitalOTHER | 1 | Jul 24, 2024 | clinicaltrials |
| NCT06518434 | A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients(CanHep) | recruiting | Phase 2 | 20 | University Medical Center GroningenOTHER | 1 | Jul 24, 2024 | clinicaltrials |
Data updated 23 days agoSource updated Nov 26, 2024source: clinicaltrials